Wells Fargo & Company Evoke Pharma Inc Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.59 - $1.07 $23 - $42	40 Added 153.85%	66 $0
Q4 2023 Feb 09, 2024	BUY	$1.05 - $1.39 $2 - $2	2 Added 8.33%	26 $0
Q3 2023 Nov 13, 2023	BUY	$0.96 - $1.73 $6 - $12	7 Added 41.18%	24 $0
Q2 2023 Aug 15, 2023	BUY	$1.39 - $2.25 $1 - $2	1 Added 6.25%	17 $0
Q3 2022 Nov 14, 2022	SELL	$1.95 - $3.43 $9 - $17	-5 Reduced 23.81%	16 $0
Q2 2022 Aug 12, 2022	BUY	$2.04 - $10.32 $42 - $216	21 New	21 $0

1.46K

Ticker EVOK
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 3,343,070
Market Cap $1.57M
Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabeti...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.